Comparative Pharmacology
Head-to-head clinical analysis: CYCLAPEN W versus DYCILL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLAPEN W versus DYCILL.
CYCLAPEN-W vs DYCILL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has a similar spectrum to ampicillin but with increased acid stability and oral absorption.
Penicillin G benzathine is a slow-release parenteral formulation of penicillin G that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections.
250 mg orally every 6 hours or 500 mg orally every 12 hours.
None Documented
None Documented
0.5-1 hour in adults with normal renal function; prolonged to 2-6 hours in renal impairment.
0.5-1 hour; prolonged in renal impairment (up to 20 hours in severe cases).
Primarily renal (90-100% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%).
Renal: approx. 60-80% unchanged by glomerular filtration and tubular secretion. Biliary/fecal: minor (less than 10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic